A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel

Cerebral Adrenoleukodystrophy (CALD) Clinical Trial

— Stargazer  

Official title:

A Postmarketing, Prospective, Multicenter, Observational, Long-Term Safety and Effectiveness Registry Study of Patients With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel (Stargazer)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06224413
• Other study ID #: REG-502
• Status: Recruiting
• Start date: March 27, 2024
• Est. completion date: December 30, 2047

Study information

• Verified date: April 2024
• Source: bluebird bio
• Contact: bluebird bio
• Phone: +1-833-999-6378
• Email: clinicaltrials[@]bluebirdbio.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The main aim of this study is to assess and describe the safety outcomes, including newly diagnosed malignancies, of patients with CALD treated with eli-cel in the post-marketing setting (tradename Skysona) and to describe major functional disability (MFD)-free survival over time in participants with more advanced early active CALD. All enrolled participants with CALD treated with eli-cel in the post-marketing setting will be followed in this study for 15 years. No investigational drug product will be administered in this study. This study will enroll 120 participants with CALD treated with eli-cel in the post-marketing setting. A subpopulation of 24 participants with more advanced early active CALD will be specifically enrolled as required by the US FDA as a condition of accelerated approval and will be considered as a separate cohort for effectiveness outcomes.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: December 30, 2047
• Est. primary completion date: December 30, 2047
• Accepts healthy volunteers: No
• Gender: Male
• Age group: N/A and older

Eligibility

Inclusion Criteria:

Participants who fulfill the following criteria will be eligible for inclusion in this Registry Study.

• Participant must be treated with eli-cel in the post marketing setting at a center in the United States (US) that participates in the Registry Study.

• Participant must have provided an informed consent and/or assent to participate in Center for International Blood and Marrow Transplant Research (CIBMTR) registry.

• Participant must have provided an informed consent and/or assent to participate in the Registry Study.

• Participant must receive follow up care by a US-based physician with the ability to submit REG-502 data.

Registry Study Subpopulation inclusion:

Twenty-four of the 120 patients in the Registry Study must meet the following inclusion criteria which will be used to create the more advanced early active CALD subpopulation:

• Participant must meet the above inclusion criteria and have a Loes score of 4.5 through 9.0 with GdE+ (gadolinium enhancement positivity) from an MRI performed before treatment with eli-cel and with NFS of 0 or 1 at baseline.

Exclusion Criteria:

There are no exclusion criteria for this Registry Study.

Related Conditions & MeSH terms

• Adrenoleukodystrophy
• Cerebral Adrenoleukodystrophy (CALD)

Intervention

Other:
• No Intervention
This is non-interventional study.

Locations

Country	Name	City	State
United States	Boston Children's Hospital	Boston	Massachusetts
United States	Minneapolis	Minneapolis	Minnesota
United States	Palo Alto	Palo Alto	California
United States	Philadelphia	Philadelphia	Pennsylvania
United States	San Francisco	San Francisco	California

Sponsors (2)

Lead Sponsor	Collaborator
bluebird bio	Center for International Blood and Marrow Transplant Research

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants who Experience Each Individual Adverse Events of Interest (AEIs)	The Sponsor considers the following events to be AEIs (which should be reported as a medically significant Serious Adverse Events [SAEs]): Any newly diagnosed malignancy; Neutrophil engraftment failure: defined as health care provider (HCP) decision to administer back-up cells or subsequent hematopoietic stem cell transplantation (HSCT) due to neutrophil recovery failure; Newly acquired HIV-1 or HIV-2 infection; Any newly diagnosed autoimmune disorders; Opportunistic infections; Grade 3 or higher cytopenias occurring more than 60 days after eli-cel infusion	Through 15 years postinfusion
Primary	Number of Participants with Newly Diagnosed Malignancies		Through 15 years postinfusion
Primary	Number of Participants with Insertional Oncogenesis		Through 15 years postinfusion
Primary	Major Functional Disability (MFD)-Free Survival	MFD-free survival is defined as time from drug product infusion to either a rescue cell administration or second transplant, MFD, or death due to any cause, whichever occurs first.	Through 15 years postinfusion
Secondary	Overall Survival (OS)		Through 15 years postinfusion
Secondary	Number of Participants with Serious Adverse Events (SAEs)		Through 15 years postinfusion
Secondary	Number of Participants with Eli-cel Related AEs		Through 15 years postinfusion
Secondary	Number of Participants with Presence of Insertional Oncogenesis in Subpopulation with Newly Diagnosed Hematologic Malignancy		Through 15 years postinfusion
Secondary	Number of Participants with Complete Remission in Subpopulation with Newly Diagnosed Hematologic Malignancy		Through 15 years postinfusion
Secondary	Relapse-free Survival in Subpopulation with Newly Diagnosed Hematologic Malignancy		Through 15 years postinfusion
Secondary	Overall Survival in Subpopulation with Newly Diagnosed Hematologic Malignancy		Through 15 years postinfusion
Secondary	Number of Participants with Clinically Significant Abnormalities by Karyotyping in Bone Marrow Aspirate in Subpopulation with Newly Diagnosed Hematologic Malignancy		Through 15 years postinfusion
Secondary	Number of Participants with Clinically Significant Abnormalities on Fluorescence In-situ Hybridization (FISH) and Next Generation Sequencing (NGS) in Subpopulation with Newly Diagnosed Hematologic Malignancy		Through 15 years postinfusion